The company's strategy includes focusing on first-line treatment opportunities and expanding awareness among cardiologists and patients. Additionally, Alnylam's efforts in expanding its healthcare field teams are expected to enhance access to AMVUTTRA upon launch. These strategic initiatives underpin Trucchio's confidence in Alnylam's potential for capturing a significant market share, justifying the reiterated Buy rating and a price target of $400 for ALNY shares.